Spyre Therapeutics Inc (SYRE) Actualités

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock PR Newswire WALTHAM...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants PR...

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Form 8-K - Current report

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential

Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its...

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy...